An engaging 3.5 day event!
SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.
SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.
The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 3,000 hematologic oncology specialists to participate in the upcoming Eleventh Annual Meeting of the Society (SOHO 2023). Click for more information and registration.
The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!
All Sessions will remain available on the Attendee Hub until October 1, 2023. Sessions are accessed through the Home page.
Early testing of MRD in bone marrow after CAR-T in MM could potentially provide prognostic information
This all-new episode of The HemOnc Pulse features Anca Prica and Abi Vijenthira, MD, discussing their analysis on the cost-effectiveness of DLBCL therapies with host Chadi Nabhan.
Tisagenlecleucel may be a “curative treatment option” for children and young adults with heavily pretreated R/R ALL.
A CD7-targeted CAR T-cell therapy was “safe and highly effective” in patients with heavily pretreated T-cell ALL or T-cell LBL.
Axicabtagene ciloleucel showed a three-year OS rate of 75% in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Certain cellular pathways were upregulated in patients with MDS who responded to immunotherapy and downregulated in those who did not
"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member